On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This dual-therapy targets a pathway ...

Our top 5 highlights from the 2025 San Antonio Breast Cancer Symposium (SABCS) include articles and interviews introducing ...

Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, ...

“Gedatolisib plus Faslodex, with or without Ibrance, represents a potential new standard of care for patients with hormone ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

Not all metastatic breast cancers behave similarly in the body. Each subtype of breast cancer has distinct characteristics, which make them more likely to behave in ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...

So in summary, HER2CLIMB-05 was a positive study. It showed that adding tucatinib for both HR-positive as well as HR-negative ...